Teeple, A., and E. Muser. “Cost Per Responder Analysis of Guselkumab Versus Adalimumab Using Efficacy Results Fromm a Head-to-Head Clinical Trial in Patients With Moderate to Severe Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 1, no. 3.1, Oct. 2017, p. s6, doi:10.25251/skin.1.supp.5.